Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

Ron Ram, Corina Herscovici, Dikla Dahan, Moshe Israeli, Juliet Dreyer, Anat Peck, Ofer Shpilberg, Moshe Yeshurun

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.

Original languageEnglish
Pages (from-to)913-917
Number of pages5
JournalLeukemia Research
Volume38
Issue number8
DOIs
StatePublished - 1 Jan 2014
Externally publishedYes

Keywords

  • GVHD
  • Hematopoietic cell transplantation
  • MMF
  • Methotrexate

Fingerprint

Dive into the research topics of 'Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil'. Together they form a unique fingerprint.

Cite this